Prosecution Insights
Last updated: April 19, 2026
Application No. 17/989,925

NUCLEIC ACID SECURITY AND AUTHENTICATION

Non-Final OA §DP
Filed
Nov 18, 2022
Examiner
GUSSOW, ANNE
Art Unit
1683
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Catalog Technologies Inc.
OA Round
1 (Non-Final)
58%
Grant Probability
Moderate
1-2
OA Rounds
3y 7m
To Grant
99%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allow Rate
186 granted / 320 resolved
-1.9% vs TC avg
Strong +44% interview lift
Without
With
+44.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
68 currently pending
Career history
388
Total Applications
across all art units

Statute-Specific Performance

§101
7.6%
-32.4% vs TC avg
§103
28.2%
-11.8% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
34.1%
-5.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 320 resolved cases

Office Action

§DP
Non-Final rejection 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. This application is a CON of 17/069,420 now a US PAT 11,535, 842, which claims benefit of 62/914,086 filed on 10/11/2019. Information Disclosure Statement 3. The information disclosure statement (IDS) submitted on 06/092023 before this office action. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. All the references cited therein have been considered by the examiner. Claim status 4. In the claim listing filed on 06/09/2023 claims 1-17 are pending in this application. Claims 18-46 are canceled. Claims 4 and 6-17 are amended. No new matter has been added. Abstract-Accepted 5. The abstract filed on 11/18/2022 has been accepted by the examiner Specification-Accepted 6. The specification filed on 11/18/2022 has been accepted by the examiner. The amendments to the specification in paragraph [0001 and 00171 have been accepted by the examiner. No new matter has been introduced. The examiner has reviewed the specification. The specification is void of hyperlink and Trademark issues. Drawings-Accepted 6. The drawings filed on 11/18/2022 has been accepted by the examiner. Double Patenting Rejection 7. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 8. Claims 1-17 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims of U.S. Patent No. 11,535,842. Although the claims at issue are not identical, they are not patentably distinct from each other because of the following reasons. 9. Regarding instant claim 1, claim 1 of ‘842 patent is drawn to a method for preparing nucleic acid molecules for use in security and authentication of an artifact, the method comprising: obtaining a library of nucleic acid molecules encoding a security token, wherein the security token comprises a string of information which uniquely identifies the artifact; and applying a chemical operation to the library encoding the security token to obtain a hashed library of nucleic acid molecules encoding a hashed token. Regarding instant dependent claims 2-17, claims of ‘842 patent are drawn to said dependent claims and therefore their subject matter is not patentably distinct. Conclusion 10. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NARAYAN K. BHAT Ph. D. whose telephone number is (571)272-5540. The examiner can normally be reached MON-THURS 9am - 6.30 pm FRI 9 am -1 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anne Gussow can be reached at 571-272-6047. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NARAYAN K BHAT/Primary Examiner, Art Unit 1683
Read full office action

Prosecution Timeline

Nov 18, 2022
Application Filed
Oct 28, 2025
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595507
METHOD AND PRODUCT
2y 5m to grant Granted Apr 07, 2026
Patent 12590170
RECOMBINANT HUMAN ANTIBODIES THAT INHIBIT THE HUMAN TISSUE KALLIKREIN 7 (KLK7) AND THEIR USE AGAINST DISEASES THAT CAUSE DESQUAMATION OF THE SKIN
2y 5m to grant Granted Mar 31, 2026
Patent 12559770
MSBI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER AND DISEASES OF THE CNS AND AS A TARGET FOR THE TREATMENT AND PREVENTION OF THESE DISEASES
2y 5m to grant Granted Feb 24, 2026
Patent 12545955
ANALYSIS OF A POLYMER
2y 5m to grant Granted Feb 10, 2026
Patent 12545956
ANALYSIS OF A POLYMER
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
58%
Grant Probability
99%
With Interview (+44.1%)
3y 7m
Median Time to Grant
Low
PTA Risk
Based on 320 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month